Trial failure after trial failure: Does it look to you like nothing works in AD treatment trials? You are not alone. Worried that the drug industry might abandon Alzheimer's just at the time when new candidate treatments, biomarkers, and better trial designs appear to come within reach, industry leaders have banded together with patient groups, academic advisors, and the regulatory agencies to jointly re-engineer the drug development process. Called Coalition Against Major Diseases, the collaborative group tries to develop freely available tools for clinical treatment trials, the motto being: "We have to make sure the future is not like the past.”